Boston Therapeutics, Inc. (BTHE) Addressing the Diabetes Epidemic with Promising Drug Candidates
Approximately 25.8 million Americans have diabetes, according to the National Diabetes Education Program, making the disease the seventh leading cause of death in the United States. To put it in monetary perspective, diabetes runs up an annual tab of $174 billion in total healthcare and related treatment costs.
Boston Therapeutics is focused on the development and commercialization of novel compounds based on complex carbohydrate chemistry to address unmet medical needs, including diabetes. The company’s current product pipeline is comprised of therapies developed to treat patient populations with Type 2 diabetes, which accounts for 90-95 percent of all diagnosed cases of diabetes in adults.
PAZ320 is Boston Therapeutics’ chewable drug candidate designed to prevent diabetes and its complications. The company believes PAZ320 is a safe and effective drug compound for people with pre-diabetes and diabetes in their daily management of blood glucose levels, fulfilling an unmet medical need of increasing proportion. In its phase 2 clinical trial, 45 percent of the patients saw a 40 percent reduction in the elevation of post meal blood sugar compared to baseline.
IPOXYN, a universal oxygen carrier, is Boston Therapeutics’ injectable drug candidate for the prevention of necrosis (premature cell death following ischemia) and ischemic conditions, which are caused by the shortage of oxygen supply to the tissue due to restriction in blood supply. Necrosis is the outcome of severe and acute injury, involved in many pathological conditions, including diabetes. For now, the only treatment for necrosis is providing oxygen by a high pressure facility, creating a crucial need to develop drugs for prevention and treatment of this pathology.
Supported by a highly dedicated management and advisory team with extensive expertise in complex carbohydrate chemistry, regulatory affairs, and clinical development, Boston Therapeutics is well-positioned to advance position as a high-potential developer of complex carbohydrate-based new chemical entities for the treatment of diabetes.
For more information, visit www.bostonti.com
Please read full disclaimers at https://disclaimer.missionir.com